Session Details

Co-Chairs:

• Erja Kerkela, PhD, Finnish Red Cross Blood Service, Finland
• Anna Pasetto, PhD, Oslo University Hospital, Norway

Speakers:

• Özcan Met, PhD, Herlev and Gentofte Hospital, Center for Cancer Immune Therapy (CCIT-DK), Denmark - Adoptive cell therapy for solid tumor up TIL now
• Stina Wickström, PhD, Department of Oncology-Pathology, Karolinska Institute, Sweden - Improving ACT therapy through combination with a DC tumor vaccine and protecting NK cells and T cells against oxidative stress 
• Víctor Cervera, PhD, Tilt Biotherapeutics, Finland - Using an engineered oncolytic virus coding for TNF alpha and IL-2 to overcome ACT-TIL limitations in solid tumors

This session will concentrate on the latest innovations concerning TIL therapies for solid cancers. Our international experts will delineate novel manufacturing methods, innovative clinical trial designs integrating TILs with alternative approaches, and the utilization of TILs in various solid tumors, including gynecological malignancies.

Session Objectives

1. Understanding the latest developments in TIL manufacturing
2. Learning about new clinical trial designs for combination therapies with TILs (e.g. oncolytic viruses)
3. Discovering new applications of TILs for solid cancers beyond melanoma